Transgene Provides Business and Financial Update for Q3 2025

Core Insights - Transgene's TG4050, an individualized neoantigen therapeutic vaccine, shows promising immunogenicity data in preventing cancer relapse, with results to be presented at SITC 2025 [1][2][3] - The company is advancing its clinical trials, with the first immunogenicity data from the ongoing Phase II trial expected in H2 2026 [1][6] - Financial updates indicate a positive trend in research tax credits and a strategic funding plan to support operations until the end of December 2026 [12][14][15] Clinical Development - TG4050 has demonstrated the ability to induce neoantigen-specific cytotoxic CD8+ T-cell responses, which can target and eliminate tumor cells, with effects detectable up to two years post-treatment [3][4] - The ongoing Phase I/II trial evaluates TG4050 as a single agent in the adjuvant treatment of HPV-negative head and neck squamous cell carcinoma (HNSCC) [4][6] - Transgene is exploring efficient regulatory pathways to expedite TG4050's development for operable HNSCC patients [7] Financial Position - For Q3 2025, Transgene reported a research tax credit of €5.8 million, up from €4.8 million in Q3 2024, reflecting ongoing clinical trial progress [12] - As of September 30, 2025, the company had €12.8 million in cash, down from €16.7 million at the end of 2024, with a net cash burn of €28.8 million for the first nine months of 2025 [13] - A new amendment to the account advance agreement with major shareholder TSGH has increased funding to €48 million, allowing the company to sustain operations through December 2026 [14][15] Future Plans - Transgene plans to present additional immunological data profiling the neoantigen-specific T-cell response at the SITC Annual Meeting [2][5] - The company is initiating start-up activities for a potential new Phase I trial in a second indication, aiming to begin once all conditions are met [8]